Schizophrenia Disorder
25
6
6
7
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 25 trials
100.0%
+13.5% vs benchmark
4%
1 trials in Phase 3/4
0%
0 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (25)
Cognitive Strategies in Early Psychosis 2
TIS for Improving Cognitive Impairment in Schizophrenia
MicroRNAs as Biomarkers in First Episode Schizophrenia
Assessment of Physical Activity, Balance, Muscle Strength, and Cognitive Function in Patients Diagnosed With Schizophrenia
dACC-Targeted Temporal Interference for Negative and Cognitive Symptoms in Schizophrenia
Mechanisms of Sulforaphane Supplementation in Alleviating Negative Symptoms and Cognitive Impairment in Schizophrenia
A Virtual Reality Mindfulness Application for Aggression in Schizophrenia
Understanding and Treating Severe and Resistant Pathological Aggression: Using Deep Brain Stimulation to Treat Resistant Aggression
A Positron Emission Tomography (PET) Study to Evaluate Dopamine D2 and D3 Receptor Occupancy by SIPI6398
Virtual Reality-Based Smoking Cessation Treatment in Patients With Schizophrenia
Incentives and Long-Acting Injectable Adherence After Involuntary Hospitalization
Improving Health Literacy in Patients With Schizophrenia Spectrum Disorder
Medication Adherence in Severe Mental Illness: a Promotion Program
Comparison of Accelerated Intermittent Theta Burst Stimulation vs High Frequency Transcranial Magnetic Stimulation (Hf-rTMS) on Cognitivesymptoms in Treatment-resistant Schizophrenia
LRFN5 and OLFM4 in Schizophrenia
Inter-Brain Synchrony in Schizophrenia
Reducing Mental Health Stigmatization Among Healthcare Workers and Students Using a Virtual Reality Protocol: The VIRTUS Protocol
KetoBrain: Brain Energy Metabolism in Schizophrenia
Understanding Mechanisms of Synaptic Degeneration Underlying Clinical Symptoms in Patients With MDs and NDs.
AI-assisted Masticatory Muscle Training in Patients With Schizophrenia